Top Medical Stocks For 2015

Can we please stop making smoking the No. 1 vice to be avoided in America?

CVS Pharmacy, the second-largest drug store chain in the United States, announced today that it will cease selling cigarettes in all its stores this year, citing the company’s commitment to health care. CVS chief medical officer, Troyen Brennan, said in a statement that, “Stopping the sale of cigarettes and tobacco will make a significant difference in reducing the chronic illnesses associated with tobacco use.”

There’s no doubt that cigarettes are unhealthy — and that second-hand smoke has exposed non-smokers to health risks as well. But CVS’ decision doesn’t affect second-hand smoke, and won’t necessarily make a steep dent in overall smoking rates. Other chains, such as Target, haven’t sold cigarettes in years.

Top Medical Stocks For 2015: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company’s Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company’s lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it ex erts its localized anti-inflammatory and analgesic effect. Transdel is the Company’s transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors’ Opinion:

  • [By John Udovich]

    So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year – making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many…) planned biotech IPOs that have recently been announced publicly:

Top Medical Stocks For 2015: Cambridge Heart Inc (CAMH)

Cambridge Heart, Inc., incorporated on January 16, 1990, is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company’s products incorporate its technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient’s heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses.

The Company’s products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States. The Company’s products have also received the Conformite Europeenne (CE) mark for sale in Europe. The Company’s first generati on HearTwave System, CH 2000 Cardiac Stress Test System and the HearTwave II System have been approved for sale by the Japanese Ministry of Health Labor and Welfare.

The Company’s 510(k) clearance allows the Company’s MTWA Test to be used to test patients with known, suspected, or at risk of ventricular tachyarrhythmia and/or sudden cardiac arrest, and allows the claim that its MTWA Test is predictive of those events. The MTWA Module is designed to work with existing cardiac stress test platforms distributed by other manufacturers as an add-on module to enable MTWA testing to be performed using the Company’s Micro-V Alternans Sensors.

The Company’s HearTwave II System, which has replaced the Company’s original HearTwave System, is used to perform both MTWA testing and standard cardiac stress testing. In addition to MTWA measurement, the Company’s HearTwave II System is a cardiac diagnostic system designed to support a range of customized protocols for the conduct of cardiac exercise stress testing. The Comp! any’s Micro-V Alternans Sensors are single patient use, multi-segment electrodes. The Company’s CH2000 is a cardiac diagnostic system designed to support a range of customized protocols for the conduct and measurement of cardiac exercise stress testing.

The Company competes with GE Medical Systems.

Advisors’ Opinion:

  • [By Peter Graham]

    Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:

    Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its Board

    Small cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.

Top Medical Stocks For 2015: Spectrum Pharmaceuticals Inc.(SPPI)

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. It markets Zevalin, a prescribed form of cancer therapy, radioimmunotherapy; and Fusilev, a novel folate analog formulation and the pharmacologically active isomer of the racemic compound, calcium leucovorin. The company?s drugs in late stage development include Apaziquone, an anti-cancer agent; and Belinostat, a histone deacytelase inhibitor. Its drugs in development also include Ozarelix a luteinizing hormone releasing hormone antagonist, which is in Phase II clinical stage; SPI-1620, a peptide agonist of endothelin B receptors, which is in Phase I clinical stage; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent, which is in preclinical stage. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Spectrum Pharmaceuticals (NASDAQ: SPPI) shares tumbled 9.77 percent to $8.18 after the company announced an offering of $100 million of convertible notes.

  • [By James E. Brumley]

    Eight months ago, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was a train wreck. Shares had plunged from $12.43 to $7.79 on the heels of bad news, and SPPI wouldn’t stop bleeding until it hit a low of $6.92 a few days after the big selloff. That bad news? A warning that its full-year sales (and particularly sales of its cancer drug Fusilev) would be well short of expectations.

  • [By Keith Speights]

    Another prime case study for this comes from Spectrum Pharmaceuticals (NASDAQ: SPPI  ) . Spectrum’s stock more than doubled from October 2011 through July 2012. However, shares plunged 55% from those highs because business dynamics changed since then. A shortage of a generic rival to Spectrum’s lead drug Fusilev was alleviated, resulting in sales slowing down considerably. 

  • [By Rich Smith]

    Spectrum Pharmaceuticals (NASDAQ: SPPI  ) has found itself a new Executive Vice President, a new Chief Financial Officer, and a new Principal Accounting Officer. They’re all the same person.

Top Medical Stocks For 2015: ResMed Inc (RMD)

ResMed Inc., (ResMed), incorporated on March 31, 1994, is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company.

Air Flow Generators

The Company produces continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Its VPAP units deliver bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. AutoSet systems are based on a technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. The Company’s Stellar 100 and 150 ventilation devices, provide both invasive and non invasive ventilation applications for adult and pediatric patients.

ResMed Inc.’s CPAP products include S8 Escape, S9 Elite and S9 Escape. Its VPAP products include VPAP III STA with QuickNav, VPAP S / VPAP IV, VPAP IV ST, S8 Auto 25, VPAP Tx Lab System, S9 VPAP S, S9 VPAP ST! , S9 VPAP Auto, S9 VPAP Adapt, S9 AutoSet CS, S9 Auto 25 and S9 VPAP COPD. The Company’s automatic positive airway pressure products include S9 AutoSet and S9 Escape Auto. Its ventilation products include Elisee 150, VS III and Stellar 100 and 150.

Masks, Accessories, Motors and Diagnostic Products

Masks, accessories, motors and diagnostic products together accounted for approximately 46% of its net revenues in fiscal 2012. Its Mask products include Activa LT, Swift LT for Her, Swift FX, Mirage SoftGel, Quattro FX, Swift FX for Her, Mirage FX, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Quattro Air and Swift FX Nano. Its diagnostic products includes ApneaLink + Oximetry and ApneaLink Plus (U.S.)

Accessories and Other Products

The Company to assist those professionals diagnosing or managing the treatment of patients have data communications and control products, such as the EasyCare, ResLin k, ResControl, ResControl II, TxControl, ResScan and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. These products include humidifiers, such as H5i and H4i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient, helping to prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. The Company’s data/patient management products include S9 Embletta Adapter, ResScan v3.14, ResTraxx v17.1., ResTraxx v18.3, ResScan v3.16 and EasyCare 1.0.

The Company competes with Philips BV, DeVilbiss Healthcare., Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corp, BMC Medical Co. Ltd and Weinmann Gerate fur Medizin GmbH + Co. KG.

Advisors’ Opinion:

  • [By Damian Illia]

    A Delaware corporation formed in 1994, ResMed Inc. (RMD) is a global leading designer, developer, manufacturer and marketer of medical products for the diagnosis, treatment and management of sleep-disordered breathing (SDB) and other respiratory disorders. For the quarter ended in Dec. 31, 2013 ResMed reported a 2 percent increase (a 1 percent increase in constant currency basis) in revenue over the quarter ended in Dec. 31, 2012. However, these earnings failed to meet analyst estimates; and not without a reason. A relatively poor performance was expected due to continued pressure in the United States, especially as a consequence of the market’s restructuring due to competitive Medicare bidding. This might also be one of the reasons why this stock still remains undervalued.

  • [By Ben Levisohn]

    Resmed (RMD) has plunged 12% to $49.50 in after-hours trading after it reported a profit of 56 cents, below estimates of 58 cents.

    Cliffs Natural Resources (CLF) has gained after it reported a profit of 68 cents, missing forecasts for 71 cents, but beat on revenue.

  • [By Seth Jayson]

    Basic guidelines
    In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven’t materialized. Is the current inventory situation at ResMed (NYSE: RMD  ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is ResMed doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 10.0%, and inventory decreased 9.3%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 9.9%, and inventory shrank 9.3%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 1.9%, and inventory dropped 14.5%.

  • [By Sean Williams]

    ResMed (NYSE: RMD  ) : 2% projected forward yield
    Like the previous companies, ResMed has operations on a global scale, but unlike the preceding device makers, its focus is on medical equipment that helps diagnose and treat sleeping disorders. Whereas growth at Smith & Nephew and Medtronic has been slow-and-go in recent quarters, ResMed has seen sales take off. In its recently reported fourth-quarter results, ResMed delivered record quarterly revenue and income of $414.6 million and $86.2 million. Revenue in its Americas and combined Europe/Asia Pacific regions rose by 11% and 12%, respectively, with the company announcing a 47% increase to its quarterly dividend. 

Top Medical Stocks For 2015: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton’s tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, t he Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin’s lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin’s lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indica tions of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company’s Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A mu lticenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phas e II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors’ Opinion:

  • [By MONEYMORNING]

    We saw this last year with such Private Briefing recommendations as The Boeing Co. (NYSE: BA) and Pharmacyclics Inc. (Nasdaq: PCYC), which rose more than 100% and 400%, respectively, following our recommendation.

  • [By Ben Levisohn]

    Somaiya and team named Gilead and Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

  • [By John McCamant]

    The company—which we consider conservative among biotech stocks—is Pharmacyclics (PCYC). Its pill is also expected to be approved for a much larger B-cell cancer market, chronic lymphocytic leukemia (CLL), by the end of February.

  • [By Anders Bylund]

    And then there’s cancer drug developer Pharmacyclics (NASDAQ: PCYC  ) . This stock had been trading like a roller coaster when the poison pill quietly got the kibosh, and continued to trade sideways for another couple of years. Then Pharmacyclics’ cancer treatments made some headway in FDA proceedings led by leukemia drug Ibrutinib, sending the stock on a rocket ride. Pharmacyclics’ returns of 2,500% since the plan change make the S&P 500’s 45% jump look like dead money. And Pharmacyclics may work together with some big partners, but remains a separate business to this day.

Top Medical Stocks For 2015: Boston Therapeutics Inc (BTHE)

Boston Therapeutics, Inc. is a development-stage company. The Company’s business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company’s non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.

SUGARDOWN

The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose us ing processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.

PAZ320

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company’s non-systemic compounds for p rediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.

IPOXYN

The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company’s pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.

Advisors’ Opinion:

  • [By CRWE]

    Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).

    Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
    Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.

Top Medical Stocks For 2015: IDEXX Laboratories Inc (IDXX)

IDEXX Laboratories, Inc., incorporated in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through three segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller segments that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do B rasil Ltda.

The Company sells a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its primary products and services are point-of-care veterinary diagnostic products, consisting of instruments and consumables and rapid assays; veterinary reference laboratory diagnostic and consulting services used by veterinarians; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; practice management systems and services and digital radiography systems used by veterinarians; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.

Companion Animal Group

The Company markets a range of in-clinic laboratory analyzers for use in providing reference laboratory quality diagnostic result s in companion animal veterinary practices, which it refers ! to as the IDEXX VetLab suite of analyzers. The Company sells two chemistry analyzers, the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, that are used by veterinarians to measure levels of certain enzymes and other substances in blood or urine for monitoring health status and assistance in diagnosing physiologic conditions. Both instruments use consumables manufactured for IDEXX by Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, based on Ortho’s dry slide technology (Catalyst Dx slides, VetTest slides or slides). In addition, the Catalyst Dx analyzer also uses dry slide electrolyte consumables manufactured by IDEXX at OPTI Medical Systems, one of its wholly owned subsidiaries. Blood tests commonly run on these analyzers include glucose, alkaline phosphatase, alanine aminotransferase (ALT), albumin, creatinine, blood urea nitrogen (BUN), and total protein. Tests are sold individually and in prepackaged panels. Both analyzers also run a urine test called urine protein:creatinine ratio, which assists in the detection of early renal disease.

The Catalyst Dx analyzer is the Company’s chemistry analyzer. The Catalyst Dx analyzer allows a veterinarian to run multiple patient samples simultaneously; to run different sample types, including whole blood, plasma, serum and urine; to perform 28 different chemistry and electrolyte tests; and to automatically calculate other parameters and ratios important to blood chemistry analysis. Its VetLyte Electrolyte Analyzer measures three electrolytes-sodium, potassium and chloride-to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Its VetStat Electrolyte and Blood Gas Analyzer measures electrolytes, blood gases, glucose and ionized calcium, and calculates other parameters, such as base excess and anion gap. These measurements aid veterinarians in diagnosing various disease states, evaluating fluid therapy choices and measuring respiratory function. The VetStat analyzer ru! ns single! -use disposable cassettes that contain various configurations of analytes. The VetStat analyzer and its cassettes are manufactured by OPTI Medical Systems.

The Company sells three hematology analyzers that assess the cellular components of blood, including red blood cells, white blood cells and platelets (also called a complete blood count (CBC)). These analyzers include the ProCyte Dx Hematology Analyzer, which uses laser-flow cytometry, optical fluorescence and laminar-flow impedance in its analysis; the LaserCyte Hematology Analyzer, which uses laser-flow cytometry technology in its analysis, and the IDEXX VetAutoread Hematology Analyzer. It also sells the Coag Dx Analyzer, which permits the detection and diagnosis of blood clotting disorders. The ProCyte Dx analyzer provides validated results for five species (canine, feline, equine, bovine and ferret) for up to 24 different blood parameters, providing a more complete picture of each patient’s health.

< p>

The SNAPshot Dx analyzer provides quantitative measurements of total thyroxine (T4), cortisol and bile acids to assist in the evaluation of thyroid, adrenal and liver function. The SNAPshot Dx analyzer also reads, interprets and records the results of many IDEXX rapid assay SNAP tests, including its canine SNAP 4Dx test, feline SNAP FIV/FeLV Combo test, canine SNAP cPL test, feline SNAP fPL test, SNAP Feline Triple test and canine SNAP Heartworm RT test. The IDEXX VetLab UA Analyzer provides chemical urinalysis and is validated specifically for veterinary use. The IDEXX VetLab Station (IVLS) connects and integrates the diagnostic information from all the IDEXX VetLab equipment and thus provides reference laboratory information management system capability. It sells the IVLS as an integral component of the Catalyst Dx, LaserCyte and ProCyte Dx analyzers and also as a standalone hardware platform.

The IVLS includes a user interface to input patient infor mation, connect with a practice management system and send i! nformatio! n to run the individual analyzers. IVLS also generates one integrated patient report incorporating all of the lab work generated by the IDEXX VetLab suite; stores, retrieves and analyzes historical patient diagnostics data, including SNAP test results; and sends and receives information from practice management systems, including the IDEXX Cornerstone system, as well as a variety of third-party systems. It sells a range of single-use, handheld test kits under the SNAP name. In addition to its single-use tests, it sells a range of microwell-based test kits under the PetChek name for canine heartworm, FIV and FeLV.

The Company offers commercial reference laboratory diagnostic and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, South Africa, China and South Korea and to bioresearch customers in the United States and Europe. The Company provides specialized veterinary consultation, telemedicine and advisory services, inc luding radiology, cardiology, internal medicine and ultrasound consulting. It develops, markets and sells practice management systems, including hardware and software, and services that run certain functions of veterinary clinics, including managing patient electronic health records, scheduling (including boarding and grooming), reminders, billing and inventory management.

The Company markets and sells two digital radiography systems for use in the small animal veterinary hospital: the IDEXX-DR 1417 and the IDEXX I-Vision CR. Its digital radiography systems use IDEXX-PACS and IDEXX EquiView PACS picture archiving and communication system (PACS) software for the viewing, manipulation, management, storage and retrieval of the digital images generated by the digital capture plate. In September 2011, the Company launched IDEXX I-Vision Mobile, an application that allows veterinarians with the IDEXX-DR 1417 and IDEXX I-Vision CR systems, as well as its digital radiog raphy systems, to request, view and send images using an iPa! d or an A! ndroid mobile tablet. This application integrates with its IDEXX-PACS software.

Water

The Company offers a range of products used in the detection and quantification of various microbiological parameters in water. Its principal products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as indicators of microbial contamination in water. These products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Its water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.

Livestock and Poultry Diagnostics

The Company sells diagnostic tests and related instrumentation that are used to detect a range of diseases and to monitor health status in livestock and poultry. Its livestock and poultry diagnostic products are purchased by government and private laboratories that provide testing services to cattle, swine and poultry veterinarians and producers. Its principal products include tests for Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS) and Bovine Spongiform Encephalopathy (BSE or mad cow disease). BVDV is a common and contagious viral infection that suppresses the immune system, making the animal susceptible to a host of other infections, impacting beef and dairy production yields as a result. PRRS is a contagious virus causing reproductive problems and respiratory diseases. BSE is a fatal neurodegenerative disease in cattle that causes a spongy degeneration in the brain and spinal cord.

< p>Other

The principal products in the Company